Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-04-24
1993-12-07
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3134
Patent
active
052683877
ABSTRACT:
3 and 4-substituted 2(5H)-furanone compounds influence the balance between bone production and bone resorption in mammals, including humans. The active compounds are administered to mammals, including humans, in an effective dose which ranges between 0.05 to 100 mg per kilogram, body weight, per day, for the purpose of influencing the balance between bone production and bone resorption, and particularly for treating osteoporosis.
REFERENCES:
patent: 2359096 (1944-09-01), Elderfield
patent: 2359208 (1944-09-01), Elderfield
patent: 4447445 (1984-05-01), Jacobs
patent: 4786651 (1988-11-01), Wheeler
patent: 4789749 (1988-12-01), Jacobs et al.
patent: 4855320 (1989-08-01), Chatterjee et al.
patent: 4874782 (1989-10-01), Bonjouklian et al.
patent: 4916241 (1990-04-01), Hayward et al.
patent: 4935530 (1990-06-01), Lee
patent: 5013850 (1991-05-01), Lee
patent: 5037811 (1991-08-01), Lee
patent: 5043457 (1991-08-01), Lee
patent: 5045564 (1991-09-01), Lee
patent: 5059611 (1991-10-01), Lee
patent: 5081147 (1992-01-01), Lee
patent: 5081261 (1992-01-01), Lee
patent: 5082954 (1992-01-01), Lee
patent: 5089485 (1992-02-01), Lee
patent: 5112853 (1992-05-01), Garst
Bonjuklian, et al., Chemical Abstracts, vol. 106, 156260c, p. 670 (1987).
Reynolds, et al, J. Am. Chem. Soc., 110, pp. 5172-5177 (1988).
Tocanne et al., Chemical Abstracts 69 76581k, p. 7146 (1968).
Deems, et al, Biochimica et Bioiphysica Acta, 917 pp. 258-268 (1987).
Scheuer et al., Journal of the American Chemical Society 100:1 p. 307 (Jan. 4, 1978).
Graziano, et al., Chemical Abstracts 107, (1987), 236559t.
Roll et al., Org. Chem. 1988, 53 3276-8.
Negishi et al., J. Org. Chem 45, pp. 5223-5225, (1980).
E. D. de Silva et al., "Tetrahedron Letters", 21:1611-1614 (1980).
Nakagawa et al., "Aldose reductase inhibitor from Palaun sponges" Chem. Abstract 106: 96126b (1987).
Tanaka, et al., The Chemical Society of Japan, Chemistry Letters, pp. 633-636 (1983).
Tanis, et al., Tetrahedron Letters, vol. 25, No. 40, pp. 4451-4454 (1984)--Furans in Synthesis 4. Silyl Furans as Butenolide Equivalents.
Graziano, et al, "Photosensitized Oxidation Of Furans", Part 12, Solvent Effects In Thermal Rearrangement Of The 2,5-Peroxides Of 2,5-Unsubstituted Furans, J. Chem, Soc., Perkin Trans, 1, (8), 1833-9, Apr. 19, 1989.
David Nettleton, et al, Inflammation Research Association, Fifth International Conference Poster Session, Phospholipase A.sub.2 Inhibition By Dihydrofuranones, Sep. 23-27, 1990.
Allergan Inc.
Baran Robert J.
Criares T. J.
Szekeres Gabor L.
Voet Martin A.
LandOfFree
Pharmaceutical compositions and method for administering 3 and 4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and method for administering 3 and 4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and method for administering 3 and 4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2016021